| Literature DB >> 28300834 |
Joel Fulton1, Bismoy Mazumder1, Jonathan B Whitchurch1, Cintia J Monteiro1, Hilary M Collins1, Chun M Chan1, Maria P Clemente1, Miguel Hernandez-Quiles1, Elizabeth A Stewart2, Winfried M Amoaku2, Paula M Moran3, Nigel P Mongan4,5, Jenny L Persson6,7, Simak Ali8, David M Heery1.
Abstract
Photoreceptor-specific nuclear receptor (PNR/NR2E3) and Tailless homolog (TLX/NR2E1) are human orthologs of the NR2E group, a subgroup of phylogenetically related members of the nuclear receptor (NR) superfamily of transcription factors. We assessed the ability of these NRs to form heterodimers with other members of the human NRs representing all major subgroups. The TLX ligand-binding domain (LBD) did not appear to form homodimers or interact directly with any other NR tested. The PNR LBD was able to form homodimers, but also exhibited robust interactions with the LBDs of peroxisome proliferator-activated receptor-γ (PPARγ)/NR1C3 and thyroid hormone receptor b (TRb) TRβ/NR1A2. The binding of PNR to PPARγ was specific for this paralog, as no interaction was observed with the LBDs of PPARα/NR1C1 or PPARδ/NR1C2. In support of these findings, PPARγ and PNR were found to be co-expressed in human retinal tissue extracts and could be co-immunoprecipitated as a native complex. Selected sequence variants in the PNR LBD associated with human retinopathies, or a mutation in the dimerization region of PPARγ LBD associated with familial partial lipodystrophy type 3, were found to disrupt PNR/PPARγ complex formation. Wild-type PNR, but not a PNR309G mutant, was able to repress PPARγ-mediated transcription in reporter assays. In summary, our results reveal novel heterodimer interactions in the NR superfamily, suggesting previously unknown functional interactions of PNR with PPARγ and TRβ that have potential importance in retinal development and disease.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28300834 PMCID: PMC5386588 DOI: 10.1038/cddis.2017.98
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469
Figure 1Novel heterodimerization interactions within the NR superfamily. (a–c) Yeast two-hybrid assays on S. cerevisiae L40 cell-free extracts co-expressing LexA–DBD fusion proteins containing the LBDs of PNR, PPARγ or TLX, in combination with a panel of AAD-NR LBDs. A single representative experiment is shown, and the data represent the mean β-galactosidase activity of three independent clones, with error bars representing the S.D. For AAD-NR LBDs where a cognate ligand is known (i.e., those NRs within the boxed area), assays were performed on cells cultured in the presence and absence of cognate ligands, as described in Materials and Methods. Note that LexA-DBD-PPARγ is activated by endogenous agonists in yeast. (d) Yeast two-hybrid assays showing the specific LBD interactions of PNR and PPARγ, but not PPARα or PPARδ; the RXRα LBD is shown to interact with all PPARs. (e) Co-immunoprecipitation of endogenous PNR and PPARγ proteins from retinal tissue lysate. Expression levels of PNR PPARγ and TLX proteins in input samples are shown
Figure 2Disruption of PNR/PPARγ complexes by disease-associated mutations Yeast two-hybrid assays showing interactions of LexA-PNR LBD constructs as indicated in combination with (a) AAD -PPARγ LBD or (b) AAD-BCL11A 1-376 containing the RID motif. The L375A is designed to disrupt PNR dimerization via helix H10/11 and ΔH12 is a C-terminally truncated mutant lacking the AF2 helix. (c) Interaction of LexA-PNR LBD wild-type or ESCS-associated variants with AAD-PPARγ LBD or (d) AAD-BCL11A 1-376. (e) Qualitative summary of the effects of LBD variants on homodimer, heterodimer and corepressor interactions of PNR. (f) Schematic highlighting the differential effects of W234S and L336P on dimerization and cofactor binding by the PNR LBD in Y2H assays. (g) Two-hybrid interactions of LexA-PPARγ LBD wild-type or mutant constructs with VP16 AAD only (white bars) or AAD-PNR LBD or AAD-RXRα LBDs (black bars). Data are the average of triplicates and error bars represent S.D.
Figure 3Repression of PPARγ-mediated transcription by PNR. (a) Reporter assays showing ligand-dependent activation of a 3xPPRE-Luciferase by PPARγ in transiently transfected U2OS cells and the effect of co-transfection of PNR wild-type and R309G expression vectors. Luciferase activity was normalized to the co-transfected β-galactosidase activity. Reporter activity in transfected cells was determined following 24-h exposure to 10−7M rosiglitazone or vehicle as indicated. Data show mean luciferase values from triplicates assays, and error bars indicate the S.E.M. The right panel is a western blot showing detection of wild-type and R309G His-PNR proteins expressed in transfected cells, detected with anti-PNR antibody. (b) EMSA assays and antibody supershifts showing binding of PNR wild-type or PNR (R309G), FLAG- PPARγ or RXRα to a DR1 element in the combinations as indicated. Double-stranded DNA probes (end labeled with γ32P) were incubated with cell-free extracts of HEK293 cells expressing recombinant NR proteins, or mock transfected as indicated (as described in Supplementary Materials and Methods). Free probes and specific NR/DNA and antibody complexes are indicated on the image. The white asterix indicates a complex containing PPARγ that is shifted by the anti-FLAG antibody, the red asterix indicates complexes containing both PPARγ and PNR(R309G). (c) Schematic representation depicting the proposed interactions of PNR and PNR(R309G) complexes with the DR1 probe
Figure 4Potential functional interactions of PNR complexes Schematic model showing (a) proposed competition for DR1 type DNA targets; (b) possible role of PNR and PPARγ complexes in cofactor switching. Red triangles denote agonist ligands. (c) Novel heterodimeric complexes involving PNR and possible competition with TRβ/RXR and PPARγ/RXR heterodimers for dimeric partners. (d) Homology model of the PNR LBD (4LOG) indicating the distinct surfaces involved in dimerization and cofactor binding. The cofactor peptide is from a superimposed alignment of the TLX LBD in complex with atrophin corepressor peptide (4XAJ)[42]